Abstract
Idarubicin, a new analogue of daunorubicin, was administered to 27 patients with advanced breast cancer in a phase II trial. The drug was given orally at a dose of 30-35 mg/m2 every 3 weeks. Twenty-two patients were evaluable for response. All evaluable patients were previously treated with one or more chemotherapeutic regimens, including an anthracycline in more than 50% of the cases. Partial remissions were obtained in 5 patients, for a response rate of 23%. The median duration of response was 191 days. Mild nausea and vomiting were common. Diarrhea, which occurred in less than 50% of the patients, was usually short-lived. Alopecia was generally minimal. Myelosuppression was the dose-limiting toxic effect. Leukopenia was frequently seen, with full recovery by day 28 in 81 % of the courses. Thrombocytopenia was less common than leukopenia. Four cases of grade 1 acute cardiac toxicity were recorded. This study suggests that idarubicin can induce regressions in advanced carcinoma of the breast, and justifies further studies in combination with other agents.
| Original language | English |
|---|---|
| Pages (from-to) | 39-42 |
| Number of pages | 4 |
| Journal | Investigational New Drugs |
| Volume | 4 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Mar 1986 |
Fingerprint
Keywords
- breast cancer
- chemotherapy
- idarubicin
ASJC Scopus subject areas
- Pharmacology
- Molecular Medicine
Cite this
Phase II trial with oral idarubicin in advanced breast cancer. / Lopez, Massimo; Di Lauro, Luigi; Papaldo, Paola; Lazzaro, Bonaventura; Ganzina, Fabrizio; Di Pietro, Nicola.
In: Investigational New Drugs, Vol. 4, No. 1, 03.1986, p. 39-42.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Phase II trial with oral idarubicin in advanced breast cancer
AU - Lopez, Massimo
AU - Di Lauro, Luigi
AU - Papaldo, Paola
AU - Lazzaro, Bonaventura
AU - Ganzina, Fabrizio
AU - Di Pietro, Nicola
PY - 1986/3
Y1 - 1986/3
N2 - Idarubicin, a new analogue of daunorubicin, was administered to 27 patients with advanced breast cancer in a phase II trial. The drug was given orally at a dose of 30-35 mg/m2 every 3 weeks. Twenty-two patients were evaluable for response. All evaluable patients were previously treated with one or more chemotherapeutic regimens, including an anthracycline in more than 50% of the cases. Partial remissions were obtained in 5 patients, for a response rate of 23%. The median duration of response was 191 days. Mild nausea and vomiting were common. Diarrhea, which occurred in less than 50% of the patients, was usually short-lived. Alopecia was generally minimal. Myelosuppression was the dose-limiting toxic effect. Leukopenia was frequently seen, with full recovery by day 28 in 81 % of the courses. Thrombocytopenia was less common than leukopenia. Four cases of grade 1 acute cardiac toxicity were recorded. This study suggests that idarubicin can induce regressions in advanced carcinoma of the breast, and justifies further studies in combination with other agents.
AB - Idarubicin, a new analogue of daunorubicin, was administered to 27 patients with advanced breast cancer in a phase II trial. The drug was given orally at a dose of 30-35 mg/m2 every 3 weeks. Twenty-two patients were evaluable for response. All evaluable patients were previously treated with one or more chemotherapeutic regimens, including an anthracycline in more than 50% of the cases. Partial remissions were obtained in 5 patients, for a response rate of 23%. The median duration of response was 191 days. Mild nausea and vomiting were common. Diarrhea, which occurred in less than 50% of the patients, was usually short-lived. Alopecia was generally minimal. Myelosuppression was the dose-limiting toxic effect. Leukopenia was frequently seen, with full recovery by day 28 in 81 % of the courses. Thrombocytopenia was less common than leukopenia. Four cases of grade 1 acute cardiac toxicity were recorded. This study suggests that idarubicin can induce regressions in advanced carcinoma of the breast, and justifies further studies in combination with other agents.
KW - breast cancer
KW - chemotherapy
KW - idarubicin
UR - http://www.scopus.com/inward/record.url?scp=0022578644&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022578644&partnerID=8YFLogxK
U2 - 10.1007/BF00172014
DO - 10.1007/BF00172014
M3 - Article
VL - 4
SP - 39
EP - 42
JO - Investigational New Drugs
JF - Investigational New Drugs
SN - 0167-6997
IS - 1
ER -